Our understanding of G protein-coupled receptor (GPCR) signalling has significantly evolved over the past decade, whereby signalling not only occurs from the plasma membrane but continues, or is reactivated, following internalisation in to endosomal compartments. The spatial organisation of GPCRs is thus essential to decode dynamic and complex signals and to activate specific downstream pathways that elicit the appropriate cellular response. For the gonadotrophin hormone receptors, membrane trafficking has been demonstrated to play a significant role in regulating its signal activity that in turn would impact at physiological and even pathophysiological level. Here, we will describe the developments in our understanding of the role of 'location' in gonadotrophin hormone receptor signalling, and how these receptors have unveiled fundamental mechanisms of signal regulation likely to be pertinent for other GPCRs. We will also discuss the potential impact of spatially controlled gonadotrophin hormone receptor signalling in both health and disease, and the therapeutic possibilities this new understanding of these receptors, so key in reproduction, offers.
Introduction
GPCRs constitute the largest family of membrane receptors and the major pharmacological target, when considering there are more than 800 different GPCRs in humans and that ~34% of commercial drugs target these receptors (Hauser et al. 2017) . Two GPCRs that are key in the endocrine regulation of reproductive functions are the luteinising hormone/chorionic gonadotrophin receptor (LHCGR) and the follicle-stimulating hormone receptor (FSHR) (Menon & Menon 2012) . Together with the thyroid-stimulating hormone receptor, they are grouped into the glycoprotein hormone receptor subfamily of the rhodopsin-like family, or Class A, of GPCRs. These comprise a unique subgroup within the Class A GPCRs due to their leucine-rich repeat-containing N-termini with a large glycoprotein extracellular ectodomain (ECD). Furthermore, the high variety of glycosylation status of the ligands makes them the most complex of protein hormones. LHCGR and FSHR play critical roles in the hypothalamic-pituitary-gonadal axis, identified via numerous studies in both animal models and diseasecausing mutations in humans (reviewed in Huhtaniemi & Themmen 2005 , Jonas et al. 2014 .
The main mechanism for GPCRs to translate messages from the extracellular environment is via coupling to distinct heterotrimeric G proteins. However, given the diverse and central roles, this group of signalling receptors play in vivo, current models of GPCR signalling incorporate an ever-increasing complexity in its signal pathways and mechanisms of regulation and may help to explain the distinct roles glycoprotein hormone receptors play in physiology. We now understand that GPCR signalling can be diversified in various ways and at different levels; receptors can associate as homomers or heteromers; splice variants of receptors can be generated with altered signalling/regulatory properties and differential post-translational modifications to modulate receptor interactions with other proteins. One mechanism that can both diversify, yet also specify, receptor signalling is membrane trafficking, and is exploited by cells to target receptors to defined cellular locations, and thus distinct signalling fates. This review will focus on membrane trafficking of gonadotrophin hormone receptors and its impact on cellular signalling. Furthermore, we will describe how gonadotrophin hormone receptors have shed light on novel cell biological pathways potentially applicable to many GPCRs, which also emphasizes the integrated nature of receptor signalling, and the critical nature of location on such signalling. We will then discuss how these cell biological mechanisms could enhance our understanding of the significance of spatial control of signalling in vivo and its implications to reproductive medicine.
Gonadotrophin hormone receptors and their ligands
Gonadotrophin hormone receptors can be divided into three domains: a large ECD (ranging from 349 to 440 aa) typical of glycoprotein hormone receptors, a transmembrane core and a C-terminal tail (C-tail). Across different species, the highest dissimilarity is in the C-tail, if we consider that human and rat gonadotrophin hormone receptors can display 90% sequence identity across the N-terminus and core portions and only 70% in their C-tails (Ascoli et al. 2002) . The extremely large and leucine-rich repeat ECD is the primary site for ligand binding. FSHR only responds to one endogenous ligand, FSH, whilst LHCGR can bind either LH or chorionic gonadotrophin (CG) . To differentiate between species where LHR binds both LH and CG or LH only, the nomenclature has been revised to LHCGR for primates and equines, and LHR for rodents and all other mammals (Troppmann et al. 2013) . However, while in humans and primates, LH and CG are products of different genes, the equine placental gonadotrophin and pituitary LH are products from the same gene (Cohen et al. 2015) . This equine placental LH/CG also has both FSHR and LHCGR activities in other species (Chopineau et al. 2001 , Park et al. 2017 . Glycoprotein hormones are heterodimers composed by one common α-subunit and one specific β-subunit linked via noncovalent association. Both subunits are subjected to N-glycosylation that impact on their bioactivity rather than receptor binding (Green & Baenziger 1988) . For FSH, two naturally occurring glycoforms have been identified, the hypo-glycosylated FSH 21/18 and the fully glycosylated FSH 24 (Walton et al. 2001) . Interestingly, these potentially have distinct activities and may be of significance to ovarian ageing (Bousfield et al. 2018) . The β-subunits of LHB and CGB also undergo differential processing, with the mature LHB peptide containing 121 aa, including one N-glycosylation site, while CG is 145 aa with two N-glycosylation sites and a unique carboxy-terminal peptide extension containing four sites of O-linked glycosylation. This confers to CGB a higher stability, greater receptor binding affinity and longer halflife (hours instead of minutes) compared to LHB (Choi & Smitz 2014 , Casarini et al. 2018 . Interestingly, recent studies suggest that LH and CG may induce even further distinct activities via LHCGR (Casarini et al. 2012 , Riccetti et al. 2017a .
Upon their release in the circulation, gonadotrophins bind their receptors, expressed in both male and female gonads, to regulate key reproductive functions including steroidogenesis, ovulation, spermatogenesis and maintenance of early pregnancy. Functional extragonadal receptors have also been reported in the uterus, endothelial cells, bone and adipose tissue (Sun et al. 2006 , Stilley et al. 2014a ,b, Li et al. 2017 , Liu et al. 2017a , Sacchi et al. 2018 , although whether these receptors are indeed expressed and functional in some of these tissues is still a matter of debate (Seibel et al. 2006 , Pakarainen et al. 2007 , Stelmaszewska et al. 2016 . The physiological functions of gonadotrophin hormone receptors are achieved through the activation of G protein-mediated pathways which, for all glycoprotein receptors, is classically Gα s /cAMP/PKA (Puett et al. 2007) . LHR was also one of the first GPCRs shown to independently bind to an additional G protein, Gα q/11 , leading to calcium release from intracellular storages, although only in the presence of high concentrations of ligand and/or receptor (Gilchrist et al. 1996 , Breen et al. 2013 . Similarly, receptor levels seem to regulate LHR coupling to Gα i in Leydig cells (Moraga et al. 1997) . FSHR was also shown to couple to additional G protein pathways: Gα q/11 , which leads to extracellular calcium influx, and Gα i2 , with subsequent mitogen-activated protein kinase (MAPK) kinase/extracellular signalregulated kinase (MEK/Erk), nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB), protein kinase B (Akt) activation in Sertoli cells and osteoclasts (Crepieux et al. 2001 , Lin et al. 2006b , Sun et al. 2006 . Furthermore, both LHCGR and FSHR are also able to activate the MAPK pathway via recruitment of the GPCR adaptor proteins, the arrestins (reviewed in Reiter et al. 2017 ), which will be discussed further below.
Regulation of gonadotrophin hormone receptor G protein signalling: desensitisation and internalisation
The archetypal model of how GPCR signal activation at the plasma membrane is regulated involves a process of rapid desensitisation and internalisation to endosomal compartments. The initial step in this model involves receptor phosphorylation by second messengeractivated kinases and/or GPCR kinases (GRKs) (Komolov & Benovic 2018) . The activated, phosphorylated receptor recruits the adaptor protein arrestin from the cytosol. Arrestins are a family of multifunctional adaptor proteins with four isoforms: arrestin-1 and -4 are restricted to the visual system where they regulate rhodopsin signalling and accordingly named 'visual arrestins' (Wilden et al. 1986 , Craft et al. 1994 , whereas the other two isoforms, arrestin-2 and -3, also called β-arrestin-1 and -2, are ubiquitously distributed and bind many GPCRs (Lohse et al. 1990 , Attramadal et al. 1992 . The arrestin-bound receptor desensitises its G protein signalling through the ability of arrestin to uncouple receptor from its G protein. Arrestin then induces clustering of receptors into clathrin-coated pits (CCPs) by its ability to bind receptor, clathrin heavy chain and core clathrin adaptor proteins, resulting in receptor internalisation (Rajagopal & Shenoy 2018) . Although this is the most extensively described model, distinct GPCRs differentially employ this system for their internalisation and desensitisation, whereby some receptors undergo clathrin-independent internalisation and distinct patterns of GRK phosphorylation, and via more recent structural and functional studies, bind arrestins in different conformations (Shukla et al. 2014 , Thomsen et al. 2016 , Cahill et al. 2017 , Eichel et al. 2018 .
In the case of FSHR and LHCGR, both receptors have been shown to internalise in a clathrin-dependent manner (Ghinea et al. 1992 ). As discussed above, internalisation and desensitisation are mediated by GRK phosphorylation, followed by β-arrestin binding. This is true for FSHR, where a cluster of five Ser/Thr residues in its C-tail has been identified as the key sites for GRK2, 5 and 6 phosphorylation (Troispoux et al. 1999) . Interestingly, while GRK 2 is predominantly involved in FSHR desensitisation by arrestin, GRK5 and 6 also promote arrestin binding but for signalling and scaffolding purposes (Kara et al. 2006 and Fig. 1 ). Conversely to FSHR, human LHCGR and murine and porcine LHR recruit arrestins independently of phosphorylation, engaging the ADP ribosylation factor 6 (ARF6) and its intracellular loop (ICL) 3, at least for rodent LHR through interaction with Aspartate 564 in the third intracellular loop (Min et al. 2002 , Mukherjee et al. 2002 . Specifically, inactive ARF6-GDP is anchored at the plasma membrane and bound to arrestin; upon ligand stimulation, activated LHR recruits the ARF nucleotide binding site opener (ARNO), which triggers the GDP-GTP exchange on ARF6 and subsequent release of arrestin; this binds the receptor via its ICL3 and mediates its desensitisation and internalisation (Mukherjee et al. 2000 and Fig. 2) . For the human receptors, specific threonine residues in the LHCGR and FSHR third intracellular loop have been identified that dictate higher rates of internalisation and β-arrestin sensitivity compared to rat LHR/FSHR (Nakamura et al. 2000 , Bhaskaran et al. 2003 . Similarly, despite the 89% sequence homology between rat FSHR and human FSHR, six amino acids in TM4, ICL3 and TM7 determine internalisation of rat FSHR to be three times faster than human FSHR (Kishi & Ascoli 2000) . Interestingly, palmitoylation of the LHCGR C-tail has been shown to negatively regulate arrestin association and internalisation (Munshi et al. 2001) . Within the past 2 years, there have been key developments in our molecular understanding of how β-arrestins engage with GPCRs. Recent structural studies have shown that β-arrestins engage active receptor in at least three forms, via the phosphorylated C-tail, the receptor core formed by the transmembrane helical bundle or both. These forms have helped to explain how β-arrestins can mediate G protein uncoupling, internalisation and yet also facilitate signalling when either as a stable or transient GPCR/arrestin complex (Shukla et al. 2014 , Kumari et al. 2016 , Thomsen et al. 2016 , Eichel et al. 2018 ). These differences in β-arrestin binding to receptor, including LHCGR and FSHR, could also dictate the additional roles these proteins have in gonadotrophin hormone receptor signalling, which will be covered in the following paragraph.
Arrestin-mediated gonadotrophin hormone receptor signalling
First identified as a negative regulator of GPCR signalling, β-arrestin's role as scaffold for different signalling proteins is now well recognised. The different roles β-arrestins play on receptor trafficking and/or signalling are determined by the conformation they adopt after binding the receptor (Shukla et al. 2014 , Kumari et al. 2016 , Thomsen et al. 2016 Figure 1 Model depicting current understanding of FSHR endocytic pathways and its signal activation. Upon FSH binding, membrane-localised FSHR activates G proteindependent cAMP production and acute ERK response. Activation of the receptor results in GRK recruitment at the CCP and subsequent phosphorylation of FSHR core and C-tail, leading to receptor desensitisation. GRKphosphorylated FSHR is recognized by β-arrestins, required for the sustained phase of FSHR signalling from the cell surface and internalisation. Both the acute G proteindependent and the sustained β-arrestindependent signalling phases contribute to FSH-induced mRNA translation. FSHR is then internalised and targeted to VEE in a GIPCdependent manner. From APPL1-positive VEEs FSHR induces cAMP and ERK signalling and recycles back to the plasma membrane. . Although more work is required to clarify the possible role of β-arrestins in gonadotropic signalling, it would not be surprising if β-arrestins modulated distinct signalling functions for the two gonadotrophin hormone receptors, considering the differences between FSHR and LHCGR at the molecular level, e.g. phosphorylation. Indeed, engagement of β-arrestin with the phosphorylated Ser/Thr clusters in the receptor C-tail is sufficient for internalisation of FSHR, but is lacking in LHCGR (Bhaskaran et al. 2003) , and although FSHR displays β-arrestin-mediated MAPK activation, this Ser/ Thr cluster is only required for receptor internalisation (Kara et al. 2006 , Piketty et al. 2006 . The concept that arrestins can adopt multiple conformations is also confirmed by recent studies with the β1AR, which could also reveal a mechanism of how gonadotrophin hormone receptor/arrestin associations mediate sustained MAPK signalling. Like LHCGR and FSHR, the β1AR induces a sustained ERK signalling profile mediated by arrestins, but intriguingly only transiently associates with arrestin at the plasma membrane, while arrestin remains associated within clathrin-associated structures (to activate signalling) in a sustained manner (Eichel et al. 2016) . To achieve this, arrestin binds to the core of β1AR only and this association promotes interaction of arrestin with membrane phosphoinositides and clathrin-associated proteins (Eichel et al. 2018) . Given the sustained ERK signalling profile of LHCGR and FSHR, that only third intracellular loop residues of LHCGR are involved in arrestin binding, and further Through the recruitment of ARNO, and subsequent β-arrestin release from membraneanchored ARF6, the receptor engages β-arrestin through its ICL3 at clathrin-coated pits (CCP), leading to desensitisation and internalisation. While in CCPs, LHCGR also binds, through its C-tail, the adaptor protein GIPC. GIPC drives LHCGR targeting to the VEE and here it disassociates. From APPL1-positive VEEs, LHCGR is both able to recycle back to the plasma membrane and activate the majority of its Gα s /PKA/cAMP and ERK responses, potentially implied to oocyte maturation and aromatase expression, respectively. similarities in these receptors with the β1AR in terms of engagement with additional adaptors and trafficking into common post-endocytic pathways (see section 'The Very Early Endosome' below), may suggest that arrestin engages with the gonadotrophin hormone receptors in this manner.
Differential engagement of either G proteins or β-arrestins to propagate the signal, due to the stabilisation of a certain active conformation of the receptor, is defined as signalling bias . This type of signalling bias is achieved by binding of different ligands (ligand bias) or by mutations in the receptor (receptor bias) (Landomiel et al. 2014) . Biased signalling based on differentiating between G protein and arrestindependent signal pathways is a pharmacologically attractive target, as for certain GPCRs, it has been shown, using animal models, that ligand-directed signalling to the arrestin-dependent pathway is beneficial or may even underlie unwanted side effects of full agonists/ antagonists. However, recent studies have challenged this model of arrestin-mediated, G protein-independent signalling of certain GPCRs. Through the use of cell lines where each G protein or arrestin was deleted via genome editing approaches (except for Gα i/o whereby the inhibitor pertussis toxin was used to generate a 'G protein zero' state when other Gα subunits were deleted), ligand-induced arrestin recruitment was still evident, yet, ERK signalling was not (Grundmann et al. 2018) (O'Hayre et al. 2017) . These findings may not necessarily suggest that bias is not possible, as arrestin could still act as a scaffold for signalling molecules, but that the ability of arrestin-mediated signalling requires an activated G protein for certain GPCRs as an upstream step in this pathway. Interestingly, a follow-up study has suggested that in such cells where arrestins are depleted by CRISPR/CAS9, compared to siRNAmediated knockdown, the former exhibited enhanced G protein signalling, offering an alternate explanation for arrestin-independent ERK signalling observed previously in these cell models and that arrestins may 'balance' ERK signalling from different pathways (Luttrell et al. 2018) . For FSHR, expression levels of the receptor can determine signalling bias to arrestin-dependent signalling pathways. Indeed, low receptor expression levels at the plasma membrane determine FSHR signalling to be dependent on β-arrestin only with no detectable cAMP signalling (Tranchant et al. 2011 ). This was revealed by studies on the A189V mutant, which is expressed at very low levels on the cell surface and non-functional with respects to Gα s /cAMP signalling (Aittomaki et al. 1995 ). Yet, when both A189V mutant and WT FSHR are expressed at equivalent low levels they are only able to trigger G protein independent MAPK activation (Tranchant et al. 2011) . Arrestindependent ERK signalling, in the absence of detectable G protein signalling, by gonadotrophin hormone receptors was also confirmed in immortalised human granulosa tumour cell line. In these cells, ERK signalling from LHCGR and FSHR mediated cell proliferation, however, knockdown of arrestins enabled FSHR to activate cAMP/PKA signalling and apoptosis, suggesting that not only receptor expression levels, but the arrestin themselves can dictate pathway bias (Casarini et al. 2016) . This may be of significance to FSHR functions during follicular and/or Sertoli cell development, where levels of proliferation and apoptosis could be tightly controlled by such mechanisms.
G proteins and β-arrestin not only can operate as distinct signalling pathways, but can co-operate in the propagation of persistent heterotrimeric G protein signalling, from intracellular endosomal compartments. For example, pivotal studies on endosomal signalling showed that sustained cAMP production from the endosomally localised PTHR is enhanced by β-arrestin (Wehbi et al. 2013) . Direct evidence of simultaneous association of β-arrestin, Gα s /βγ heterotrimer and GPCR was recently provided by single particle EM of chimeras of β2-adrenergic receptor (β2AR) with the V2 vasopressin receptor (V2R) C-tail, where persistent β-arrestin associations via serine/threonine phosphorylation sites within the C-tail of the receptor enables simultaneous G protein binding to the receptor core and formation of the so-called megaplexes (Thomsen et al. 2016) . Both the existence and downstream significance of β-arrestin-G protein cooperation has started to be investigated for FSHR. In both HEK293 and Sertoli cells this integrative action, rather than parallel, is fundamental to achieve FSH-dependent ribosomal assembly and mRNA translation (Trefier et al. 2018 and Fig. 1 ). Conversely to the above studies with PTHR and β2AR/V2R, FSHR is not physically involved in the formation of this signalling complex and may provide further support for a catalyticmediated activation of β-arrestin by FSHR as has been shown for β1AR (Eichel et al. 2018) .
Post-endocytic sorting of gonadotrophin receptors
Following internalisation, GPCRs are sorted from endosomes to either a recycling pathway back to the plasma membrane or to the lysosomal pathway for degradation. Most receptors engage one or both of these pathways with very distinct kinetics. The interest in studying these pathways is due to the important role they have in determining the temporal pattern of GPCR/G protein signalling, by regulating the amount of cell surface receptor and that these pathways can be altered pharmacologically and in disease (Hanyaloglu & von Zastrow 2008) . However, more recent signalling models of GPCRs illustrate additional roles for these intracellular trafficking pathways as platforms for signalling, including G protein signalling (Irannejad et al. 2015 , Pavlos & Friedman 2017 . Our understanding of how cells sort GPCRs into these divergent post-endocytic fates has illustrated that these mechanisms are tightly regulated at multiple steps. These detailed mechanisms have been covered by us and others in recent reviews and will not be described in detail here except for the following fundamental features in order to discuss what is known about gonadotrophin hormone receptor sorting and its impact on signalling and physiology.
GPCRs sorted for degradation are trafficked from early endosomes (EEs) to RAB7-positive late endosomes, leading to involution of receptors to form multivesicular bodies (MVBs), where subsequent fusion with lysosomes results in receptor degradation. It must be noted that even receptors targeted to the recycling pathway will undergo degradation if chronically stimulated as part of the overall mechanism of downregulation. The canonical pathway for sorting of many types of membrane cargo, not just GPCRs, is via cargo ubiquitination at lysine residues and engagement with endosomal sorting complex required for transport (ESCRT)-dependent degradation (reviewed in Hislop & von Zastrow 2011 , Kennedy & Marchese 2015 .
GPCRs targeted to a recycling pathway are sorted within EEs to recycle via RAB4-positive recycling endosomes. These GPCRs require specific cis-acting sorting sequences in their C-tails to enter this trafficking pathway; hence, recycling is referred to as a sequencedirected, or regulated, recycling mechanism. On the contrary, receptors that do not require sorting sequences (e.g. transferrin receptor) undergo default recycling, which occurs with the bulk membrane flow. A defining feature of these sorting sequences is that they are essential for recycling, as removal results in rapid receptor degradation; furthermore, if added to the C-tail of a GPCR normally targeted to degradation, it will re-route that GPCR to the recycling pathway. Regulated recycling was first identified for the archetypal GPCR, the β2AR, where this sorting sequence is a type 1 PDZ-binding sequence or 'PDZ ligand' (Cao et al. 1999 , Hirakawa et al. 2003 . PDZ proteins are scaffold proteins so called after the first three proteins identified to have this common PDZ domain, namely postsynaptic density 95 (PSD95)/discs large (Dlg)/zonula occludens-1 (Zo-1). Initial studies with the β2AR suggested the interacting PDZ domain containing protein partner responsible was Ezrin-Radixin-Moesin (ERM)-binding phosphoprotein-50 (EPB50) also called Na + / H + exchange regulatory factor 1 (NHERF-1). However, GPCRs with PDZ ligands can interact with different PDZ proteins (He et al. 2006) , potentially with unique receptor functions. Indeed, the endosomal PDZ protein sorting nexin-27 (SNX27) was also shown to bind β2AR and to be essential for post-endocytic trafficking of this receptor to the recycling pathway (Lauffer et al. 2010) . Several GPCRs that are targeted to a regulated recycling pathway do not contain PDZ type 1 ligands, displaying highly unique receptor C-tail recycling sequences corresponding to unknown interacting protein partners (Hanyaloglu & von Zastrow 2008 , Marchese et al. 2008 . This high diversity in recycling sequences across GPCRs suggests that they bind specific cytoplasmic proteins and is particularly relevant for the human gonadotrophin hormone receptors that are targeted to a regulated recycling pathway, which will be discussed below.
For GPCRs targeted to either degradative or recycling pathways, there is a plethora of examples showing that both common and receptor-specific sorting mechanisms exist and that regulated sorting is not a one-step mechanism occurring via a protein interaction with the GPCR-sorting sequence or ubiquitinated lysine, but a complex, multi-step system, driven also by the signalling from the GPCR. Indeed, studies on gonadotrophin hormone receptor trafficking highlight the interconnected nature of post-endocytic sorting and signalling. The primary post-endocytic sorting pathway of both rodent and human FSH-FSHRs is recycling back to the plasma membrane via specific residues in the receptor C-tail that does not indicate any potential binding partners such as a PDZ protein (Krishnamurthy et al. 2003) . More recently, it has been shown that palmitoylation of three conserved cysteines in FSHR C-tail may regulate recycling (Melo-Nava et al. 2016) . As the primary role of this post-translational modification is biosynthetic processing of the receptor to the plasma membrane, its role in recycling could be due to the reduced expression and signalling, or conformational changes, leading to altered binding with putative sorting machinery, although sensitivity to arrestin-mediated internalisation was unaffected (Melo-Nava et al. 2016) .
Interestingly for LHCGR, its post-endocytic sorting fate varies across species due to differences in C-tail sequences. Thus, internalised rat, mouse and porcine LHR are predominantly directed to a degradative pathway, whilst human LHCGR is primarily recycled back to the plasma membrane, however, under chronic hormone stimulation, it will be targeted to a degradative pathway (Kishi et al. 2001) . The human LHCGR C-tail also undergoes palmitoylation, although primarily involved in negatively regulating internalisation rate, in turn, this also impacts on the amount of receptor that is downregulated following chronic hCG stimulation (Kawate & Menon 1994 , Lazari et al. 1998 , Munshi et al. 2001 . A number of residues have been identified that is necessary and sufficient for the post-endocytic trafficking of human LHCGR, which is not present in the rodent LHR C-tails and underlies their divergent sorting behaviour. Human LHCGR requires the specific residues within the last 17 amino acids of the receptor. The first sequence to be recognised was the GTALL in the very distal end of the LHCGR C-tail (Kishi et al. 2001) , with G 687 T 688 residues in the GTALL sequence being sufficient to sustain LHCGR recycling (Galet et al. 2003) , but also more upstream residues within the last 17 amino acids were identified including Cys 699 and more marginally Leu 683 (Galet et al. 2004) . Unlike the FSHR, the adaptor protein that binds this recycling sequence in LHCGR has been identified as the PDZ protein GIPC (Gα i -interacting protein, C-terminus), with LHCGR interacting specifically with the PDZ domain of this protein to mediate its recycling (Hirakawa et al. 2003 ). An intriguing question is why has the human LHCGR C-tail evolved to direct receptors to a recycling pathway, while the rodent LHR traffics to an opposing postendocytic route? One possibility to explain the ability of human receptors to recycle is that primate LHCGR have two endogenous ligands; this could represent a further mechanism to alter signalling responses activated by each ligand, although both LH and hCG induce receptor recycling (Hirakawa et al. 2003 , Jean-Alphonse et al. 2014 . The rodent LHR also internalises very slowly compared to the human LHCGR, thus, one could suggest that the net effect of both, when considering internalisation and sorting, is a system to maintain surface receptor, which could be physiologically advantageous in female reproduction during the time of LH surge in maintaining a signal response. Moreover the distinct trafficking profile of the human LHCGR may suggest additional signalling functions and will be discussed in the following section.
The very early endosome: a sorting and signalling station for gonadotrophin hormone receptors
The classic view of GPCR internalisation as a way to temporarily, or permanently, desensitise plasma membrane G protein signalling has now been revised. Extensive evidence from numerous GPCRs demonstrate that internalised receptors continue to activate, or reactivate, G protein signalling from intracellular compartments, and that this spatial compartmentalisation is critical for cells to decode signalling into specific downstream cellular functions from common second messenger signalling molecules, such as cAMP (Lohse & Calebiro 2013 , Irannejad et al. 2015 , Pavlos & Friedman 2017 .
Our studies conducted on gonadotrophin hormone receptor trafficking have unveiled unexpected mechanisms on how different GPCRs can differentiate their activity post internalisation (Jean-Alphonse et al. 2014) . These studies were initially driven to understand the role of the different GPCR recycling sequences, and their distinct interacting partners, on GPCR activity by employing the β2AR and LHCGR, which are both Gα s -coupled receptors that internalise via similar mechanisms and undergo regulated recycling, yet via distinct recycling sequences and PDZ proteins. Through live imaging of LHCGR trafficking, it was evident this receptor internalised into physically smaller endosomes, that were closer to the plasma membrane, compared to the β2AR, and that these smaller LHCGR endosomes were devoid of EE markers EE antigen 1, PI3P and Rab5 (Jean-Alphonse et al. 2014) . Mechanistically, the targeting of LHCGR to these smaller endosomes was dependent on receptor interactions with GIPC early during endocytosis, as loss of interaction between LHCGR and GIPC, either via a mutant LHCGR lacking the last 17 amino acids or via depleting cellular levels of GIPC, inhibited receptor recycling due to the rerouting of receptor to EEs. Thus, this compartment was termed very early endosomes (VEEs), as receptors required targeting to this compartment for sorting to a recycling pathway (Jean-Alphonse et al. 2014) . This not only demonstrates that regulated sorting of GPCRs can occur from compartments other than the EE, but also suggests that these recycling sequences may encode multiple functions at distinct points throughout the endocytic life cycle of the receptor. In the case of LHCGR, engagement with GIPC in clathrin-coated pits directs the receptor to distinct endosomes. Internalisation of LHCGR to VEEs was also necessary to activate and maintain a sustained ERK signalling response to LH. To further demonstrate that the EE was not involved in LHCGR sorting and signalling, Rab5a/b/c was depleted from cells, which did not impair LHCGR trafficking or ERK signalling. Intriguingly, β1AR and FSHR also internalised to small VEE-like endosomes, and loss of GIPC inhibited liganddependent ERK signalling from these GPCRs (JeanAlphonse et al. 2014) . While β1AR was known to interact with GIPC via its C-tail (Hu et al. 2003) , this result was initially surprising for FSHR as its C-tail recycling sequence contains no PDZ ligand. However, there may be clues from its ability to directly interact with the adaptor protein containing PH domain, PTB domain and leucine zipper motif (APPL1), which a subpopulation of VEEs contains and is a protein that is also able to directly bind to GIPC (Lin et al. 2006a) , further supporting the hypothesis that LHCGR and FSHR could share common sorting compartments and machinery (Figs 1 and 2) .
APPL1 is so far the only known protein present on the VEEs, suggesting a functional role of this adaptor protein within this compartment (Jean-Alphonse et al. 2014 . APPL1 is an adaptor protein, which lacks catalytic activity but is composed by various protein and membrane interacting domains (Liu et al. 2017b) . It is known to represent an intermediate early endosomal compartment, positive for RAB5, prior to conversion to EEA1 endosomes (Zoncu et al. 2009 ). However, APPL1 vesicles are present in other endosomal populations, including those that do not have RAB5 (Kalaidzidis et al. 2015) . This is relevant for VEEs, which do not contain RAB5 (Jean-Alphonse et al. 2014) and indeed under conditions that inhibit RAB5, LHCGR recycling is enhanced (Gulappa et al. 2011) . In addition to its role as an endosomal marker, APPL1 has also been shown to interact with more than 30 proteins: Rabs, receptors such as FSHR, EGF receptor, insulin receptor, adiponectin receptor, androgen receptor, kinases and phosphatases like protein kinase B (Akt), PI3K and OCRL, and adaptor proteins like GIPC. Thus, APPL1 can act to integrate between different trafficking and signalling pathways from the endomembrane (Diggins & Webb 2017) . APPL1 has been associated primarily with positive regulation of signalling; for example, it tethers GIPC to the nerve grow factor receptor TrkA, necessary for MAPK activation (Lin et al. 2006a) . Interestingly, APPL1 forms a complex with FSHR (via its intracellular loops), APPL2, Akt and FOXO1 and propagates FSHtriggered PI3K/Akt activation, inositol-1,4,5-triphosphate production and calcium release (Nechamen et al. 2004 , Dias et al. 2010 , Thomas et al. 2011 .
We have recently identified new roles for APPL1 in LHCGR and FSHR trafficking and signalling from the VEE . While interactions with GIPC were essential for directing gonadotrophin hormone receptors to the VEE, we understood little how receptors could exit the VEE and recycle to the plasma membrane. Unlike GIPC, APPL1 was not required for GPCR localisation at the VEE; however, it was essential for receptor recycling. The Gα s -cAMP-PKA pathway activated by LHCGR was also necessary to drive this recycling and resulted in APPL1 phosphorylation at serine 410. This phosphorylation step was key in driving APPL1-dependent recycling, thus demonstrating how GPCR signalling is integrated with trafficking. This theme is further highlighted by the findings that APPL1 negatively regulates cAMP from VEE-targeted GPCRs, and critically that the primary location of this cAMP signalling is from VEEs . How APPL1 achieves this in terms of regulation of GPCR/G protein coupling is still unknown; yet, it was identified that the unphosphorylated form of APPL1 was required to do this. This suggests that distinct populations of APPL1, phosphorylated and unphosphorylated forms, have distinct and opposing functions on the gonadotrophin receptors. These populations could be either distinct endosomes or distinct forms of APPL1 on the same endosome, and indeed super-resolution and TIRF imaging of LHCGR, APPL1 and a nanobody recognising the active Gα s (nb37), suggested both are possible . Overall, it reveals an exquisitely regulated VEE network where signalling and trafficking are tightly controlled by the action of the adaptor protein APPL1. How the related protein APPL2, which has common and distinct functions to APPL1, operates in the VEE is unknown, although FSHR has been shown to form a complex containing both proteins (Nechamen et al. 2007 ); thus, this may have similar or distinct roles in gonadotrophin hormone receptor trafficking.
A critical outstanding question is understanding the downstream role of VEE targeting, and the strict spatial control of ERK and cAMP signalling from LHCGR and FSHR. These VEE pathways are likely to be conserved as APPL1-dependent recycling of LHCGR was evident in primary human endometrial stromal cells, a cell type previously shown to express functional LHCGR, though has predominantly been studied in relation to hCG signalling in early pregnancy (Bernardini et al. 2013 . Translating these findings to human gonads, however, is more technically challenging. Interestingly, it has been shown that siRNA knockdown of APPL1 in bovine theca cells enhances LH-mediated androgen production (Comim et al. 2013a) . Given cellular depletion of APPL1 increases LH/LHCGRmediated cAMP signalling in HEK 293 cells ) is consistent with this and may suggest a role for APPL1 and the VEE in tight regulation of LH-mediated steroidogenesis. A more recent study provides direct evidence for the spatial control of LH-mediated cAMP signalling in the mouse ovarian follicle and the resumption of meiosis in the oocyte (Lyga et al. 2016 and Fig. 2) . Although rodent LHR displays distinct properties in terms of internalisation kinetics and post-endocytic sorting pathways from human LHCGR, perhaps the trafficking properties of rodent LHR may be distinct in the ovary compared to heterologous cells, not only due the distinct intracellular environment of these cell types, but also interaction with other GPCRs, including the FSHR. Heteromers of LHCGR and FSHR have been reported by several groups (Feng et al. 2013 , Mazurkiewicz et al. 2015 , Jonas et al. 2018 , and given both human FSHR and rodent FSHR exhibit similar trafficking properties, perhaps interactions of LHR with FSHR may enable greater internalisation and spatial control of signalling in response to LH. An additional possibility is that the distinct trafficking profiles of human LHCGR and rodent LHR may enable differential spatial control of signal pathways, which then translates to distinct downstream functions, as indicated by known differences in phenotypes of certain disease-causing mutations in human gonadotrophin hormone receptors compared to animal models harbouring the same mutations (Huhtaniemi 2006 ). This in turn raises further questions if other receptor signalling pathways could be spatially regulated via the VEE such as cGMP, a signalling molecule that diffuses from the granulosa cells to the oocyte holding it in prophase until activation by LH/LHR lowers cGMP levels or Gα q -PLC signalling pathway, which is activated under high hormone and receptor levels and thought to be key during ovulation (Breen et al. 2013 , Egbert et al. 2014 . The signalling profiles of human gonadotrophin hormone receptors are also conserved from heterologous cells to the gonads, indeed LHCGR induces sustained ERK activation in human ovarian granulosa cells that negatively regulates expression of aromatase (Casarini et al. 2012) , a signalling profile that may result from VEE-localised LHCGR, as shown in HEK293 cells (Jean-Alphonse et al. 2014 and Fig. 2) . Overall, compartmentalised signalling of internalised GPCRs at distinct intracellular comportments represents a mechanism for cells to diversify signalling even from the same pathway (e.g. cAMP/PKA) to perhaps distinct functional consequences. It also raises the intriguing possibility that receptor activity or cellular decoding, of common signals can be reprogrammed by altering the compartment the receptor is targeted to, via altering expression of key proteins in this pathway, e.g. GIPC, APPL1. Such a model may explain how LHR and FSHR activation of a common pathway, cAMP/PKA, underlies distinct functions during the dynamic extracellular environment throughout the menstrual cycle.
Future perspectives
Our current understanding of gonadotrophin hormone receptors demonstrates that they are exquisite examples of GPCRs that achieve signalling diversification via multiple strategies; these include the use of different protein machinery (e.g. GRKs) for their internalisation and/or desensitisation, and signal transmitters (distinct G proteins and β-arrestins) than can temporally regulate signalling. Furthermore, they are also prototype receptors for understanding novel facets of GPCR function, namely the tight spatial control of GPCR signalling via existence of new endosomal compartments. Whether such pathways are then perturbed in disease and if we can harness these properties of GPCRs therapeutically needs to be addressed.
Several key outstanding questions remain regarding the molecular intricacies and downstream roles of these novel intracellular compartments. The increasing advances in super-resolution imaging capabilities and optogenetics to cell biology (Spangler & Bruchas 2017 , Sigal et al. 2018 ) is highly pertinent to the small VEE (~400 nm) (Jean-Alphonse et al. 2014) , where structures such as microdomains and tubules would be beyond the diffraction limit of light at (<250 nm) (Abbe 1873). Thus, the ability to follow an individual receptor activated at the plasma membrane and to track that receptor as it traffics through the VEE system, engaging with its signalling machinery, and in turn monitor the downstream cellular function of this compartmentalised signalling, is potentially possible. To understand the in vivo significance of these novel intracellular compartments to gonadotrophin hormone receptor signalling is critical yet challenging. Given the speciesdependent differences in LHCGR vs LHR trafficking, animal models may not be appropriate to uncover the physiological significance of the VEE. Thus, these emerging models of gonadotrophin receptor action could be applied to reassess known disease-causing mutations, polymorphisms and disorders involving altered gonadotrophin hormone action, in order to aid uncovering their roles in human systems. To date, there is only one reported FSHR disease-causing mutation with characterised effects on endocytosis, specifically N431I is an activating mutation displaying constitutive activity but impaired ligand-induced desensitisation and internalisation (Casas-Gonzalez et al. 2012) .
A well-characterised SNP in FSHR, N680S, which determines poorer responsiveness to FSH in women bearing the N variant compared to the S carriers, has been shown to temporally alter cAMP, ERK1/2 and CREB responses in human granulosa cells (Nordhoff et al. 2011 , Casarini et al. 2014 . Interestingly, infertile men harbouring the 680N variant over the 680S respond better to FSH treatment as assessed by improved DNA fragmentation index of their spermatozoa (Simoni et al. 2016) . These phenotypes might highlight an altered arrestin-dependent signalling and/or altered trafficking of FSHR to endosomal compartments where they are unable to quench or activate their signalling responses. Altered gonadotrophin action has been reported in women with polycystic ovarian syndrome (PCOS) as one of the known diagnostic hallmarks of PCOS is hyperandrogenaemia (Comim et al. 2013b ). This enhanced LH-mediated androgen production may be a result of altered LHCGR endosomal location or retention in APPL1-negative VEEs, leading to the known increased androstenedione production by LHCGR in theca cells, especially as loss of APPL1 in bovine theca cells increases LH-mediated androgen production (Comim et al. 2013a) . Given the critical role internalisation has on LHCGR and FSHR signalling, and APPL1 and GIPC mediate sorting and signalling activity of these receptors, it is interesting to highlight the link between development of certain cancers such as ovarian epithelial cancer, APPL1 and gonadotrophin hormones (as the incidence of this type of cancer is higher in individuals exposed to elevated levels of circulating gonadotrophins (Choi et al. 2007) ). It has been reported that increased APPL1 levels are associated with greater invasiveness of ovarian cancer (Zhao et al. 2010) , suggesting the possibility of a detrimental hyper-VEE function in this pathological condition. Given the increasing reports of gonadotrophin hormone receptors in extragonadal tissues such as bone and adipose (Sun et al. 2006 , Liu et al. 2017a , there may be future roles for altered spatial regulation of these GPCRs in obesity, type 2 diabetes and osteoporosis.
With such a large superfamily of signalling receptors, governing central roles in most physiological systems, GPCRs are likely to remain a prominent drug target for the foreseeable future. Harnessing or manipulating the spatial control of GPCR signalling is already being targeted for novel therapeutic strategies as it offers the ability to specifically manipulate a subset of receptor activities, which in turn results in higher selectivity in its action and potentially fewer off target effects. For example, blocking endosomal signalling from the neurokinin 1 receptor and calcitonin gene-related peptide receptor has been shown to be an effective nociceptive target in animal models (Jensen et al. 2017 , Yarwood et al. 2017 . Biased ligands between G protein and arrestin-mediated activities are also of current high interest, with some in clinical development (Violin et al. 2014, Smith et al. 
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https://rep.bioscientifica.com 2018). As the physiological/pathophysiological roles of spatial control of GPCR signalling are understood, drug target strategies could accommodate these evolving models of gonadotrophin hormone receptor signalling. In terms of pharmaceutical development in targeting LHCGR and FSHR, a number of small-molecule positive or negative allosteric compounds have been produced. However, the role of these small molecules in spatial control or biased signalling remains to be determined. These were originally developed for their possible use in assisted reproductive technology due to their oral availability and a drive to find compounds with lower side effects compared to recombinant hormones (Nataraja et al. 2015) . Some of these cell permeable molecules exhibit pharmacochaperone properties (Newton et al. 2016) and even different pharmacological and signalling profiles between the two gonadotrophin hormone receptors (Ayoub et al. 2016) . It is then tempting to assume that if allosteric molecules induce signalling bias towards one pathway rather than another, such as between G protein or arrestin, in a similar way to endogenous ligands have been reported (e.g. LH vs hCG (Casarini et al. 2012 , Riccetti et al. 2017a ), they could also induce 'location bias', by stabilising receptor conformations which facilitate their interaction with adaptor proteins that target receptors to specific cellular compartments. In summary, the increasing complexity of the cell biological pathways and regulatory mechanisms that govern gonadotrophin hormone receptor signalling in space and time are likely to accelerate our understanding of how these GPCRs function in vivo and also underlie mechanisms when their function is perturbed in disease. This is not only true for the gonadotrophin hormone receptors, but could aid a more general understanding of GPCR signalling and sorting mechanisms for other members of this superfamily. Integrating these advances at the molecular and cellular level in gonadotrophin hormone receptor signalling with physiological models and clinical medicine will truly facilitate the ability to pharmacologically target receptor signalling at a spatial level with high precision, in order to create efficacious and specific therapeutics of the future.
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